Alternative polyadenylation reprogramming of MORC2 induced by NUDT21 loss promotes KIRC carcinogenesis.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
22 09 2023
Historique:
received: 01 07 2022
accepted: 15 08 2023
medline: 25 9 2023
pubmed: 22 9 2023
entrez: 22 9 2023
Statut: epublish

Résumé

Alternative polyadenylation (APA), a posttranscriptional mechanism of gene expression via determination of 3'UTR length, has an emerging role in carcinogenesis. Although abundant APA reprogramming is found in kidney renal clear cell carcinoma (KIRC), which is one of the major malignancies, whether APA functions in KIRC remains unknown. Herein, we found that chromatin modifier MORC2 gained oncogenic potential in KIRC among the genes with APA reprogramming, and moreover, its oncogenic potential was enhanced by 3'UTR shortening through stabilization of MORC2 mRNA. MORC2 was found to function in KIRC by downregulating tumor suppressor DAPK1 via DNA methylation. Mechanistically, MORC2 recruited DNMT3A to facilitate hypermethylation of the DAPK1 promoter, which was strengthened by 3'UTR shortening of MORC2. Furthermore, loss of APA regulator NUDT21, which was induced by DNMT3B-mediated promoter methylation, was identified as responsible for 3'UTR shortening of MORC2 in KIRC. Additionally, NUDT21 was confirmed to act as a tumor suppressor mainly depending on downregulation of MORC2. Finally, we designed an antisense oligonucleotide (ASO) to enhance NUDT21 expression and validated its antitumor effect in vivo and in vitro. This study uncovers the DNMT3B/NUDT21/APA/MORC2/DAPK1 regulatory axis in KIRC, disclosing the role of APA in KIRC and the crosstalk between DNA methylation and APA.

Identifiants

pubmed: 37737260
pii: 162893
doi: 10.1172/jci.insight.162893
pmc: PMC10561724
doi:
pii:

Substances chimiques

3' Untranslated Regions 0
MORC2 protein, human 0
Transcription Factors 0
Nudt21 protein, human 0
Cleavage And Polyadenylation Specificity Factor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Endocrinol Metab (Seoul). 2017 Dec;32(4):413-421
pubmed: 29271615
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Urol Int. 2008;80(4):398-404
pubmed: 18587251
Mil Med Res. 2021 Nov 24;8(1):60
pubmed: 34819142
Cancer Sci. 2019 Jan;110(1):135-146
pubmed: 30407715
J Mol Endocrinol. 2016 Aug;57(2):F29-34
pubmed: 27208003
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Biochim Biophys Acta Mol Cell Res. 2018 Dec;1865(12):1869-1877
pubmed: 30262434
Nucleic Acids Res. 2018 Nov 2;46(19):10340-10352
pubmed: 30053103
Bio Protoc. 2017 May 05;7(9):e2253
pubmed: 34541242
Neoplasia. 2022 Mar;25:18-27
pubmed: 35078134
J Clin Oncol. 2005 Jan 1;23(1):133-41
pubmed: 15625368
Nat Rev Neurol. 2018 Jan;14(1):9-21
pubmed: 29192260
Oncogene. 2018 Aug;37(35):4887-4900
pubmed: 29780166
Biomark Res. 2020 Nov 25;8(1):67
pubmed: 33292571
Nat Rev Genet. 2019 Oct;20(10):599-614
pubmed: 31267064
Nat Commun. 2014 Nov 20;5:5274
pubmed: 25409906
J Urol. 2007 Dec;178(6):2655-9
pubmed: 17945286
Onco Targets Ther. 2021 Feb 17;14:1117-1129
pubmed: 33628035
Mol Cell. 2020 May 21;78(4):752-764.e6
pubmed: 32333838
Nat Rev Mol Cell Biol. 2017 Jan;18(1):18-30
pubmed: 27677860
Sci Rep. 2021 Mar 15;11(1):6047
pubmed: 33723286
Cold Spring Harb Protoc. 2020 Sep 1;2020(9):100024
pubmed: 32873727
Oncogene. 2021 Mar;40(11):2051-2064
pubmed: 33619322
Br J Cancer. 2006 Dec 18;95(12):1701-7
pubmed: 17133271
Gut. 2020 Jul;69(7):1193-1205
pubmed: 31582403
Clin Transl Med. 2022 Jul;12(7):e970
pubmed: 35802820
Genes Dis. 2019 Oct 25;8(1):61-72
pubmed: 33569514
Oncogene. 2016 Apr 21;35(16):2087-97
pubmed: 26234674
Nat Biotechnol. 2016 Aug;34(8):875-80
pubmed: 27398791
Cell Death Dis. 2021 May 19;12(6):512
pubmed: 34011928
Clin Cancer Res. 2006 Sep 1;12(17):5040-6
pubmed: 16951219
Cancer Res. 2019 Jul 15;79(14):3714-3724
pubmed: 31064846
Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166541
pubmed: 36113752
Cancer Res. 2018 Oct 15;78(20):5848-5862
pubmed: 30143523
Genomics Proteomics Bioinformatics. 2017 Oct;15(5):287-300
pubmed: 29031844
Cancer Sci. 2021 Apr;112(4):1443-1456
pubmed: 33453148
Cell Death Differ. 2018 Dec;25(12):2086-2100
pubmed: 29555977
Autophagy. 2020 Jun;16(6):1061-1076
pubmed: 32401166
Hum Pathol. 2018 Jun;76:58-67
pubmed: 29555576
Leg Med (Tokyo). 2005 Jul;7(4):274-7
pubmed: 15946886

Auteurs

Yuqin Tan (Y)

Department of Kidney Transplantation, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

Tong Zheng (T)

Department of Kidney Transplantation, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

Zijun Su (Z)

The First Affiliated Hospital, Faculty of Medical Science, Jinan University, Guangzhou, Guangdong, China.

Min Chen (M)

Department of Stomatology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

Suxiang Chen (S)

Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Western Australia, Australia.

Rui Zhang (R)

Department of Kidney Transplantation, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

Ruojiao Wang (R)

Department of Kidney Transplantation, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

Ke Li (K)

Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

Ning Na (N)

Department of Kidney Transplantation, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH